Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC
First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
More News: Allergy | Allergy & Immunology | Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma